Try our Advanced Search for more refined results
Securities and Exchange Commission v. Aveo Pharmaceuticals, Inc. et al
Case Number:
1:16-cv-10607
Court:
Nature of Suit:
Judge:
Firms
Government Agencies
-
February 05, 2018
Ex-Aveo Exec Fights SEC Penalty, Says He's Learned Lesson
A former Aveo Pharmaceuticals Inc. executive continued to argue in Massachusetts federal court Monday that he should not have to pay a fine or be barred from leadership positions over the Securities and Exchange Commission's allegations that he deceived investors about Aveo's flagship kidney cancer drug, saying he had learned his lesson.
-
January 17, 2018
Ex-Aveo Exec Says SEC Exaggerated Role In Investor Fraud
Aveo Pharmaceuticals Inc.'s former chief medical officer told a Massachusetts federal court Tuesday that he shouldn't have to pay a fine or be barred from leadership positions because the U.S. Securities & Exchange Commission exaggerated his alleged role in deceiving investors about Aveo's kidney cancer drug, Tivo.
-
November 09, 2017
Ex-Aveo Exec's Penalty In SEC Deal Up To Magistrate Judge
A Massachusetts magistrate judge will decide whether Aveo Pharmaceuticals Inc.'s former chief medical officer should pay a civil penalty under a deal that would resolve the U.S. Securities and Exchange Commission's allegations that he hid from investors the Food and Drug Administration's concerns about its flagship kidney cancer drug.
-
March 29, 2016
Aveo Pays $4M To End SEC Claims It Misled Investors
Massachusetts-based biotechnology company Aveo Pharmaceuticals Inc. will pay $4 million to settle the U.S. Securities and Exchange Commission's allegations it hid from investors the Food and Drug Administration's concerns over its flagship kidney cancer drug, the SEC said Tuesday.
- ← Previous
- 1
- 2
- Next →